Summary
BeOne Medicines Ltd. (ONC), a clinical-stage biopharmaceutical company, is focused on discovering and developing innovative molecularly targeted and immuno-oncology drugs for cancer treatment. As of March 2017, the company has four clinical-stage drug candidates: BGB-3111 (BTK inhibitor), BGB-A317 (PD-1 inhibitor), BGB-290 (PARP inhibitor), and BGB-283 (RAF dimer inhibitor). These candidates are in various stages of clinical trials globally, with a significant focus on China where the company believes it can leverage a distinct regulatory pathway for faster approvals. BeOne Medicines has developed a proprietary cancer biology platform that aims to improve drug discovery by incorporating advanced models that better mimic tumor-immune system interactions. The company's strategy involves advancing its pipeline through global development, pursuing combination therapies, and leveraging its platform to discover new candidates. BeOne Medicines retains global rights for its pipeline assets, with limited past collaborations that have since been repurchased or terminated. The company has successfully raised substantial capital through public offerings to fund its extensive research and development activities, though it continues to incur net losses. Investors should note the significant risks associated with clinical development, regulatory approvals, competition, and the need for future financing.
Financial Highlights
46 data points| Revenue | $1.07M |
| Cost of Revenue | $0 |
| Gross Profit | $1.07M |
| R&D Expenses | $98.03M |
| SG&A Expenses | $20.10M |
| Operating Expenses | $118.13M |
| Operating Income | -$117.06M |
| Net Income | -$119.22M |
| EPS (Basic) | $-0.30 |
| Shares Outstanding (Basic) | 403.62M |
Key Highlights
- 1BeOne Medicines is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, particularly molecularly targeted drugs and immuno-oncology agents.
- 2The company has four clinical-stage drug candidates: BGB-3111 (BTK inhibitor), BGB-A317 (PD-1 inhibitor), BGB-290 (PARP inhibitor), and BGB-283 (RAF dimer inhibitor), all advancing through clinical trials.
- 3BeOne Medicines utilizes a proprietary cancer biology platform designed to improve drug discovery and development, especially for combination therapies.
- 4The company has a significant operational presence and strategic focus in China, believing it offers regulatory advantages for faster drug approvals.
- 5Financing has been secured through multiple public offerings, providing substantial capital to fund ongoing and future research and development efforts.
- 6Despite progress, the company continues to incur significant net losses and anticipates further losses as it advances its pipeline and seeks regulatory approvals.